Mehul R Chorawala
Overview
Explore the profile of Mehul R Chorawala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pandya D, Parikh R, Gena R, Kothari N, Parekh P, Chorawala M, et al.
Mol Biol Rep
. 2025 Mar;
52(1):296.
PMID: 40063135
No abstract available.
2.
Mistry P, Singh S, Chorawala M, Prajapati B, Kapoor D
Chem Biodivers
. 2024 Dec;
e202402258.
PMID: 39714589
Diabetes is a medical condition that belongs to the group of chronic diseases that affect how the body processes glucose, the primary source of energy for cells. Glucose comes indirectly...
3.
Shah D, Chorawala M, Pandya A, Kothari N, Prajapati B, Parekh P
Curr Med Sci
. 2024 Dec;
44(6):1155-1174.
PMID: 39676146
Cystic fibrosis (CF) is a hereditary disorder characterized by mutations in the CFTR gene, leading to impaired chloride ion transport and subsequent thickening of mucus in various organs, particularly the...
4.
Israni D, Raghani N, Soni J, Shah M, Prajapati B, Chorawala M, et al.
Pharmaceutics
. 2024 Oct;
16(10).
PMID: 39458608
emerges as a noteworthy candidate for its medicinal potential, particularly in wound healing. This review article explores the efficacy of cannabis oil in reducing reactive oxygen species (ROS) during the...
5.
Mistry P, Chorawala M, Sivamaruthi B, Prajapati B, Kumar A, Chaiyasut C
Curr Diabetes Rev
. 2024 Aug;
PMID: 39136514
Diabetes mellitus (DM) is an intricate metabolic disorder marked by persistent hyperglycemia, arising from disruptions in glucose metabolism, with two main forms, type 1 and type 2, involving distinct etiologies...
6.
Dave B, Chorawala M, Shah I, Shah N, Bhagat S, Prajapati B, et al.
Mol Biol Rep
. 2024 Jul;
51(1):835.
PMID: 39042283
Glucagon-like Peptide-1 (GLP-1) receptor agonists (GLP-1RAs) emerged as a primary treatment for type-2 diabetes mellitus (T2DM), however, their multifaceted effects on various target organs beyond glycemic control opened a new...
7.
Shah D, Chorawala M, Mansuri M, Parekh P, Singh S, Prajapati B
Naunyn Schmiedebergs Arch Pharmacol
. 2024 Jun;
397(11):8603-8631.
PMID: 38935128
Biogenic metallic nanoparticles (NPs) have garnered significant attention in recent years due to their unique properties and various applications in different fields. NPs, including gold, silver, zinc oxide, copper, titanium,...
8.
Pandya D, Parikh R, Gena R, Kothari N, Parekh P, Chorawala M, et al.
Mol Biol Rep
. 2024 Jun;
51(1):701.
PMID: 38822973
Background: Disabled 2 (DAB2) is a multifunctional protein that has emerged as a critical component in the regulation of tumor growth. Its dysregulation is implicated in various types of cancer,...
9.
Shah A, Dabhade A, Bharadia H, Parekh P, Yadav M, Chorawala M
Z Naturforsch C J Biosci
. 2024 May;
79(9-10):235-266.
PMID: 38807355
Theranostics refers to the combination of diagnostic biomarkers with therapeutic agents that share a specific target expressed by diseased cells and tissues. Nuclear medicine is an exciting component explored for...
10.
Shah N, Dave B, Shah K, Shah D, Maheshwari K, Chorawala M
Cell Biochem Biophys
. 2024 Apr;
82(2):501-520.
PMID: 38594547
The Disabled-2 (DAB2) protein, found in 80-90% of various tumors, including breast cancer, has been identified as a potential tumor suppressor protein. On the contrary, some hypothesis suggests that DAB2...